Efficacy of antiretroviral compounds against Toxoplasma gondii in vitro

文献类型： 外文期刊

第一作者： Wang, Jin-Lei

作者： Wang, Jin-Lei;Li, Ting-Ting;He, Jun-Jun;Bai, Meng-Jie;Liang, Qin-Li;Zhu, Xing-Quan;Cong, Wei;Elsheikha, Hany M.;Cong, Wei

作者机构：

关键词： Toxoplasma gondii; Antiretroviral compounds; Cerebral toxoplasmosis; Drug repurposing; HIV; AIDS

期刊名称：INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS （ 影响因子：5.283； 五年影响因子：5.209 ）

ISSN： 0924-8579

年卷期： 2019 年 54 卷 6 期

页码：

收录情况： SCI

摘要： The obligate intracellular parasite Toxoplasma gondii can infect nearly all warm-blooded animals, including humans. Although infection with this parasite is generally benign, severe illness may occur in infected individuals if their immunity becomes less competent, such as in human immunodeficiency virus (HIV)-infected patients. In this study, the inhibitory activity of 44 commonly used antiretroviral compounds was determined against T. gondii in vitro. Of the 44 tested antiretroviral compounds, 14 showed potency against T. gondii at IC50 concentrations (concentration inhibiting T. gondii tachyzoite growth by 50%) ranging from 1.18 +/- 2.21 mu M (nelfinavir) to 18.89 +/- 1.87 mu M (trovirdine). Of the 14 potent antiretroviral compounds, 7 are HIV-1 protease inhibitors. This study also investigated whether co-administration of these 14 antiretroviral compounds interferes with the anti-T. gondii activity of existing anti-T. gondii drugs, namely sulfadiazine and pyrimethamine. The results showed no significant interaction between any of the 14 tested antiretroviral compounds and pyrimethamine or sulfadiazine. These results warrant investigation of whether administration of the lead antiretroviral drugs with highly potent anti-T. gondii activity to HIV patients may help to limit the occurrence of toxoplasmic encephalitis. (C) 2019 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

分类号：

  • 相关文献
作者其他论文 更多>>

微信小程序